LOXO 195

Drug Profile

LOXO 195

Alternative Names: LOXO195

Latest Information Update: 17 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Array BioPharma
  • Developer Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 05 Jul 2017 Loxo Oncology initiates an expanded access programme for Cancer before July 2017 (NCT03206931)
  • 01 Jun 2017 Phase-I/II clinical trials in Cancer in USA (PO)
  • 31 May 2017 The US FDA approves IND application for LOXO 195 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top